Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $18.1952W HIGH $37.50
Volume
3.96 K
Value Traded
614.93 K
Short % Float
5.45%
-2.01%Week
-16.5%1 Month
-16.67%3 Month
-9.85%6 Month
-95.56%5 Year
-95.56%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
78.64 M
EPS (TTM)
-18.69
P/E Ratio
-
Ent. Value
54.29 M
Total Shares
3.83 M
Float Shares
1.72 M
Insiders
55.19%
Institutions
43.15%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
PTHS Catalyst Timeline
Dated clinical, regulatory and corporate events for Pelthos Therapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pelthos Therapeutics Inc.
81Total events
8Upcoming
20Tier-1 (high impact)
2023 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Oral PresentationPresentation
CEO Scott Plesha to present at Jefferies Global Healthcare Conference
▲First Patient DosedCT2000Trial
First patient dosed in Phase 1b/2a trial of CT2000 for eye pain
eye painsource ↗
◆Oral PresentationPresentation
CEO Scott Plesha to participate in fireside chat at 38th Annual ROTH Conference
◆Quarterly UpdateCorporate
Fourth Quarter and Full Year 2025 Financial Results Conference Call
◆Oral PresentationPresentation
CEO presentation at Oppenheimer 36th Annual Healthcare Life Sciences Conference
▲Debt Royalty FinancingCorporate
Secured up to $50 million senior secured term loan facility from Horizon Technology Finance
◆AcquisitionXEGLYZEApprovedCorporate
Pelthos Therapeutics acquires Xeglyze (abametapir) from Hatchtech Pty Ltd.
head lice infestationsource ↗
▲Debt Royalty FinancingCorporate
Entered into $50.0 million senior secured term loan facility with Horizon Technology Finance
▲AcquiredXEGLYZEApprovedCorporate
Acquisition of XEGLYZE announced in January 2026
head lice infestationsource ↗
◆Oral PresentationPresentation
CEO Scott Plesha fireside chat at Piper Sandler 37th Annual Healthcare Conference
▲Partnership / LicenseZelsuvmiApprovedCorporate
PBM agreement for ZELSUVMI formulary inclusion
molluscum contagiosumsource ↗
◆AcquisitionXEPIApprovedCorporate
Acquired U.S. commercialization rights to Xepi (ozenoxacin) Cream, 1%
impetigosource ↗
▼Equity OfferingCorporate
Closed $18.0 million private convertible notes financing in November 2025
▲Quarterly UpdateZelsuvmiApprovedCorporate
2,189 ZELSUVMI units prescribed in October 2025
molluscum contagiosumsource ↗
▲Timing GuidanceZelsuvmiApprovedPresentation
Anticipated strong continued growth for ZELSUVMI in Q4 2025
molluscum contagiosumsource ↗
▲Quarterly UpdateZelsuvmiApprovedCorporate
2,716 ZELSUVMI units prescribed by 1,169 unique prescribers in Q3 FY2025
molluscum contagiosumsource ↗
◆Oral PresentationPresentation
H.C. Wainwright 27th Annual Global Investment Conference Presentation
◆Oral PresentationPresentation
Pelthos Therapeutics to present at Wells Fargo Healthcare Conference
▲Product LaunchZelsuvmiApprovedPost-Market
Launched ZELSUVMI (berdazimer) topical gel 10.3% for molluscum contagiosum
molluscum contagiosumsource ↗
◆AcquisitionCorporate
Merger of Channel Therapeutics with LNHC, Inc. and concurrent $50.1M private placement
▲Product LaunchZelsuvmiApprovedPost-Market
ZELSUVMI launched for molluscum in adults and pediatric patients one year and older
molluscum contagiosumsource ↗
▲FDA ApprovalZelsuvmiApprovedFDA Decision
FDA approval of Zelsuvmi for Molluscum contagiosum
Molluscum contagiosumsource ↗
▲AcquisitionXEPIApprovedCorporate
Acquisition of XEPI added to portfolio
infectious skin conditionsource ↗
▲Preclinical PoCCT2000Preclinical
Preclinical endpoints achieved in animal models of CT2000
eye painsource ↗
▲Poster PresentationZelsuvmiApprovedPresentation
Poster presentation at Fall Clinical 2024 showing Zelsuvmi efficacy
Molluscum contagiosumsource ↗
▲First Patient DosedCC8464Trial
Completed Phase I trials in healthy volunteers
idiopathic small fiber neuropathy, erythromelalgia, neuropathic painsource ↗
◆Trial InitiationCC8464Trial
Prepare to relaunch CC8464 program for chronic pain treatment
idiopathic small fiber neuropathy, erythromelalgia, neuropathic painsource ↗
Past FDA Catalysts and PDUFA Decisions
How PTHS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-01-05 | Zelsuvmi (berdazimer sodium) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every PTHS program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Friedberg Ezra MDirector | Sell | -534 81,066 held | $26.03 | 07/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PTHS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0.4 % (-33.3 %) | 5.39 M | 256.60 K | 0.33% ( 840.00) |
PTHS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PTHS ranks across every disease it competes in
Competitive Position is a premium feature
See how PTHS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPTHS News
PTHS▲ +0.2%today
Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%
Pelthos Therapeutics has announced expanded formulary coverage for ZELSUVMI (berdazimer) topical gel, now reaching 127 million commercially covered lives. The new agreements with a major Pharmacy Benefit Manager and a regional health plan enhance access to the treatment for molluscum contagiosum. This expansion aligns with Pelthos' commitment to improving patient access to their innovative therapies.
Read more →PTHSPelthos Therapeutics Announces Second Quarter 2026 Financial Results
Pelthos Therapeutics reported a strong performance for Q2 2026, with Zelsuvmi net product revenue increasing by 45% to $15.4 million. The company dispensed 11,925 units of Zelsuvmi, marking a 48% increase from the previous quarter. Despite a net loss of $(23.4) million, management remains optimistic about future growth and the upcoming commercialization of additional products.
Read more →PTHS▼ -6.4%on this news
Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
Pelthos Therapeutics Inc. will report its second quarter 2026 financial results on August 13, 2026. The company will host a conference call at 8:30 a.m. ET to discuss the results, followed by a Q&A session. Pelthos is known for its innovative treatments for cutaneous infectious diseases.
Read more →PTHS▲ +6.4%on this news
Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
Pelthos Therapeutics Inc. has announced its 2026 Annual Meeting of Stockholders to be held virtually on September 29, 2026. Stockholders of record by August 4, 2026, will be eligible to vote. The meeting date has changed by more than 30 days from the previous year, affecting the submission of stockholder proposals.
Read more →PTHSPelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
Pelthos Therapeutics Inc. has been added to the Russell 3000E Growth Benchmark and other Russell indexes effective June 29, 2026. This inclusion reflects the company's growth and strategic advancements since becoming public. CEO Scott Plesha expressed optimism that this will increase the company's visibility and investment opportunities.
Read more →PTHSPelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Pelthos Therapeutics Inc. will participate in the Jefferies Global Healthcare Conference on June 4, 2026. CEO Scott Plesha is scheduled to present and engage in one-on-one investor meetings. The company is dedicated to developing therapeutic products for infectious diseases, including its lead product ZELSUVMI® for molluscum contagiosum.
Read more →PTHSLegal Disclaimer This presentation of Pelthos Therapeutics Inc. ("we", "us", "our" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other secu
Pelthos Therapeutics Inc. presented at the Jefferies Global Healthcare Conference, highlighting its focus on innovative dermatological products. The company has launched Zelsuvmi, a treatment for molluscum contagiosum, and it anticipates further product launches in the pipeline, including Xepi and Xeglyze. The management team has significant experience within the pharmaceutical industry, which supports the firm's development strategy amid potential market challenges.
Read more →PTHS▲ +6.5%on this news
Pelthos Therapeutics Announces First Quarter 2026 Financial Results
Pelthos Therapeutics reported a 17% increase in ZELSUVMI revenue for Q1 2026, reaching $10.7 million. The company dispensed 7,884 units, marking a 25% rise from the previous quarter. Management expressed optimism about ongoing growth, supported by a strengthened sales force and a new $50 million loan facility. However, the company also reported a net loss of $(10.2) million.
Read more →PTHSPelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026
Pelthos Therapeutics Inc. has announced that it will report its first quarter 2026 financial results on May 14, 2026. The company will host a conference call at 8:30 a.m. Eastern time to discuss these results, allowing for a question-and-answer session afterwards. Pelthos is focused on innovative therapies for cutaneous infectious diseases, including its lead product ZELSUVMI™. Additional details about the conference call and corporate information were also provided in the announcement.
Read more →PTHSPelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
Pelthos Therapeutics Inc. announced participation in the Piper Sandler Spring Biopharma Symposium on April 16, 2026, in Boston. CEO Scott Plesha is set to hold one-on-one investor meetings, signaling the company's commitment to engaging with potential investors. Pelthos focuses on innovative treatments for infectious diseases, with its leading product being ZELSUVMI™, a topical gel approved for home use against Molluscum contagiosum. This event may enhance the company's visibility and focus on unmet patient needs.
Read more →PTHSPelthos Therapeutics Announces CFO Transition
Pelthos Therapeutics Inc. announced the appointment of John M. Gay as the new Chief Financial Officer, effective April 10, 2026. Mr. Gay succeeds Francis Knuettel II and previously served as Senior Vice President, Finance & Accounting at Pelthos. CEO Scott Plesha expressed confidence in Gay's capabilities to support the company's ongoing growth and praised Knuettel's contributions post-merger with Channel Therapeutics. Pelthos focuses on innovative therapeutics for infectious diseases, notably ZELSUVMI™ for Molluscum contagiosum.
Read more →PTHSPelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
Pelthos Therapeutics has announced the dosing of the first patient in a Phase 1b/2a clinical trial for CT2000, intended to treat eye pain associated with dry eye disease. This marks the first human trial for CT2000, which has shown promising results in pre-clinical animal studies. The trial will assess the safety and clinical efficacy of the eye drop formulation. Results are expected by the end of 2026, highlighting the potential value of CT2000 in addressing unmet therapeutic needs in eye care.
Read more →PTHSPelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results
Pelthos Therapeutics reported a significant growth in net product revenue for its product ZELSUVMI, achieving $9.1 million in the fourth quarter of 2025. The company also highlighted a remarkable 129% increase in units of ZELSUVMI dispensed from the third to fourth quarters. Pelthos has broadened its product offerings with the acquisition of XEPI and XEGLYZE, enhancing its portfolio in the dermatology sector. CEO Scott Plesha expressed confidence in ongoing growth strategies supported by recent financial activities, including significant private financing and a senior secured term loan.
Read more →PTHS▲ +5.4%on this news
Pelthos Therapeutics to Present at 38th Annual ROTH Conference
Pelthos Therapeutics Inc. announced that CEO Scott Plesha will participate in a fireside chat at the 38th Annual ROTH Conference on March 23, 2026. Investors can arrange one-on-one meetings through ROTH representatives. A live webcast of the chat will be available on the company's website, with a replay accessible for 90 days post-event.
Read more →PTHSPelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
Pelthos Therapeutics Inc. will announce its fourth quarter and full year 2025 financial results on March 19, 2026. The announcement includes a conference call scheduled for 8:00 a.m. Eastern Time, allowing for a question-and-answer session. The company is recognized for its commitment to developing therapies for infectious diseases.
Read more →PTHS▲ +5%on this news
Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Pelthos Therapeutics Inc. announced that CEO Scott Plesha will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The management team will also host one-on-one meetings with investors during the event. The presentation will be available via webcast and on the company's website.
Read more →PTHSPelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance
Pelthos Therapeutics has secured a senior secured term loan facility of up to $50 million from Horizon Technology Finance. This funding will support the commercialization of its lead product, ZELSUVMI, an FDA-approved treatment for molluscum contagiosum, along with other products. The deal is designed to be minimally dilutive to existing shareholders and aims to strengthen Pelthos' balance sheet.
Read more →PTHSCorporate Presentation Q1 2026 2 Legal Disclaimer This presentation of Pelthos Therapeutics Inc. ("we", "us", "our" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Lit
Pelthos Therapeutics Inc. has released a corporate presentation highlighting its innovative product, Zelsuvmi, which launched in July 2025 as the first at-home treatment for Molluscum contagiosum. The presentation outlines a strong market potential with an anticipated revenue of $175 million by 2028 from this product alone. The company has also made strategic acquisitions, including FDA-approved dermatological products Xepi and Xeglyze, to enhance its portfolio. An experienced management team backs these initiatives, aiming to establish a significant presence in the biopharmaceutical market.
Read more →About Pelthos Therapeutics Inc.
Headquarters4020 STIRRUP CREEK DRIVE, DURHAM, NC, 27703
BIOPHARMAWATCH ELITE PLUS
Trade the next PTHS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime